Kyverna Therapeutics Inc. (NASDAQ: KYTX) Stock Information | RedChip
Image

ASK REDCHAT ANYTHING ABOUT KYVERNA THERAPEUTICS INC.

Kyverna Therapeutics Inc. (NASDAQ: KYTX)
Listen to this Section


$7.67
-0.2850 ( -3.58% ) 259.2K

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.

Clinical Trial Pipeline Stages


Drug Name Stage
KYV-101DetailsLupus nephritis Phase 1

Market Data


Open $7.67
Previous Close $7.95
Volume 259.2K
Market Cap $475.42M
Day Range $7.67 - $8.03
52 Week Range $2.52 - $13.67
Shares Outstanding 60.80M
Change % -3.58%
Net Change ▼ -0.2850
Insider Ownership -0.27%
Exchange NASDAQ
SectorHealthcare
Industry
IPO Year2024
CountryUnited States
UnderwriterJ.P. Morgan, Morgan Stanley, Leerink Partners, Wells Fargo Securities, more

Insider Ownership Transactions

Total Amount Purchased: 1,139,027.00

Date Type Amount Purchased Purchaser
2024-06-10 Sale -9636.00 Walker Karen Marie
2024-05-29 Sale -10870.00 Jones Ryan Alexander
2024-02-14 Buy 2713868.00 Bain Capital Life Sciences Investors, LLC
2024-02-14 Sale -3787940.00 SEIDENBERG BETH C
2024-02-14 Sale -4523924.00 Cohen Fred E
2024-02-14 Buy 4523924.00 Vida Ventures, LLC
2024-02-14 Sale -3787940.00 Westlake BioPartners Fund I, L.P.
2024-02-13 Buy 3216119.00 GILEAD SCIENCES, INC.
2024-02-12 Buy 2805426.00 Northpond Ventures III GP, LLC

SEC Filings


Form Type Description Pages Date
10-q Quarterly Reports 72 Nov 12, 2025
8-k 8K-related 11 Nov 12, 2025
8-k 8K-related 11 Nov 03, 2025
8-k 8K-related 13 Oct 29, 2025
8-k 8K-related 38 Oct 29, 2025
8-k 8K-related 10 Sep 25, 2025
8-k 8K-related 11 Aug 12, 2025
10-q Quarterly Reports 69 Aug 12, 2025
3 Insider transactions 2 Jul 01, 2025
4 Insider transactions 1 Jul 01, 2025

Latest News


× Before browsing our site, please accept our cookies policy